In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: 

• Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL 
• BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL 
• IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL 

Presenters: 

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

• CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
• SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
• CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
• Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
• BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:

• ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR
• CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer 
• Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer
• DUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration 
• MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator’s choice of CT in platinum-resistant ovarian cancer with high expression of FRα
• Patient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancer

Presenters:
Kathleen Moore, MD, MS
Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Nicoletta Colombo, MD, PhD
Associate Professor of Obstetrics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: 

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:

• NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer
• ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer
• Phase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancer
• Randomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancer
• GOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancer

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Linda Duska, MD, MPH
Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc.

Link to full program: bit.ly/424E3Uq

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: 

• Considerations with administration, including access challenges
• Sequencing Therapies
• Future developments with BCMA-targeted therapies

Presenters:

Suzanne Lentzsch, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Medical Center 
New York, New York

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.

Link to full program: bit.ly/41YEOO6

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:

• Overall approach to treatment
• Use of JAK inhibitors for treating myelofibrosis
• Treating patients with low platelets
• Defining JAK inhibitor failure
• Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches

Presenters: 

John Mascarenhas, MD
Professor of Medicine

Icahn School of Medicine at Mount Sinai

Director, Adult Leukemia Program

Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute

New York, New York

Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Enterprise Senior Vice President, Atrium Health

President, Enterprise Cancer Service Line

Vice Dean for Cancer Programs, Wake Forest University School of Medicine

Professor of Medicine, Wake Forest University School of Medicine 

Winston-Salem, North Carolina

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: 

• Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice 
• The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients 
• Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them 
• Administration of adjuvant olaparib with other available adjuvant systemic therapies
• Tolerability of single-agent PARP inhibitors 

Presenters:

Banu Arun, MD
Professor, Breast Medical Oncology 
Director, Clinical Cancer Genetics 

University of Texas MD Anderson Cancer Center 

Houston, Texas 

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology 
Director, PGY2 Oncology Residency Program 

UK HealthCare 

Assistant Adjunct Professor

UK College of Pharmacy 

Lexington, Kentucky

Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
Nurse Practitioner 
Breast Oncology

Texas Oncology Baylor Sammons Cancer Center 

Dallas, Texas 

Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. 

Link to full program:
https://bit.ly/42VeUMM

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:

• Expression patterns and function of the claudin family of proteins in normal gastric tissues
• Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology
• Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers
• Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection
• Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs

Presenters:

Samuel Klempner, MD
Associate Professor
Department of Medicine
Division of Hematology-Oncology
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Gregory Botta, MD, PhD
Clinical Professor of Medicine
Department of Medicine
Division of Hematology & Oncology
University of California San Diego
La Jolla, California

Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb.

Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):
bit.ly/3lQxPrq

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. 

The topics covered include:

• When to use cytoreduction therapies and which therapies to use in low-risk patients
• Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
• Experts’ thoughts on therapy options in higher-risk patients

Presenters:

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall, MD
Assistant Professor 
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida
 

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.

Topics discussed include:

• Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
• Indirect methods for measuring asparaginase activity
• Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
• Considerations for use of asparaginase in special populations (eg, high BMI, older age)

Presenters:

Program Director
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Emily Curran, MD
Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci
Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.

Link to full program:
http://bit.ly/3YXkLyj